tetano
Editor, Senior Moderator
Vaccine. 2014 Mar 11. pii: S0264-410X(14)00211-4. doi: 10.1016/j.vaccine.2014.02.038. [Epub ahead of print]
Protective immunity to H7N9 influenza viruses elicited by synthetic DNA vaccine.
Yan J1, Villarreal DO2, Racine T3, Chu JS2, Walters JN2, Morrow MP1, Khan AS1, Sardesai NY1, Kim JJ1, Kobinger GP3, Weiner DB4.
Author information
Abstract
Despite an intensive vaccine program influenza infections remain a major health problem, due to the viruses' ability to change its envelope glycoprotein hemagglutinin (HA), through shift and drift, permitting influenza to escape protection induced by current vaccines or natural immunity. Recently a new variant, H7N9, has emerged in China causing global concern. First, there have been more than 130 laboratory-confirmed human infections resulting in an alarmingly high death rate (32.3%). Second, genetic changes found in H7N9 appear to be associated with enabling avian influenza viruses to spread more effectively in mammals, thus transmitting infections on a larger scale. Currently, no vaccines or drugs are effectively able to target H7N9. Here, we report the rapid development of a synthetic consensus DNA vaccine (pH7HA) to elicit potent protective immunity against the H7N9 viruses. We show that pH7HA induces broad antibody responses that bind to divergent HAs from multiple new members of the H7N9 family. These antibody responses result in high-titer HAI against H7N9. Simultaneously, this vaccine induces potent polyfunctional effector CD4 and CD8T cell memory responses. Animals vaccinated with pH7HA are completely protected from H7N9 virus infection and any morbidity associated with lethal challenge. This study establishes that this synthetic consensus DNA vaccine represents a new tool for targeting emerging infection, and more importantly, its design, testing and development into seed stock for vaccine production in a few days in the pandemic setting has significant implications for the rapid deployment of vaccines protecting against emerging infectious diseases.
Copyright ? 2014. Published by Elsevier Ltd.
KEYWORDS:
DNA vaccine, H7N9, Hemagglutinin (HA)
PMID:
24631084
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/24631084
Protective immunity to H7N9 influenza viruses elicited by synthetic DNA vaccine.
Yan J1, Villarreal DO2, Racine T3, Chu JS2, Walters JN2, Morrow MP1, Khan AS1, Sardesai NY1, Kim JJ1, Kobinger GP3, Weiner DB4.
Author information
Abstract
Despite an intensive vaccine program influenza infections remain a major health problem, due to the viruses' ability to change its envelope glycoprotein hemagglutinin (HA), through shift and drift, permitting influenza to escape protection induced by current vaccines or natural immunity. Recently a new variant, H7N9, has emerged in China causing global concern. First, there have been more than 130 laboratory-confirmed human infections resulting in an alarmingly high death rate (32.3%). Second, genetic changes found in H7N9 appear to be associated with enabling avian influenza viruses to spread more effectively in mammals, thus transmitting infections on a larger scale. Currently, no vaccines or drugs are effectively able to target H7N9. Here, we report the rapid development of a synthetic consensus DNA vaccine (pH7HA) to elicit potent protective immunity against the H7N9 viruses. We show that pH7HA induces broad antibody responses that bind to divergent HAs from multiple new members of the H7N9 family. These antibody responses result in high-titer HAI against H7N9. Simultaneously, this vaccine induces potent polyfunctional effector CD4 and CD8T cell memory responses. Animals vaccinated with pH7HA are completely protected from H7N9 virus infection and any morbidity associated with lethal challenge. This study establishes that this synthetic consensus DNA vaccine represents a new tool for targeting emerging infection, and more importantly, its design, testing and development into seed stock for vaccine production in a few days in the pandemic setting has significant implications for the rapid deployment of vaccines protecting against emerging infectious diseases.
Copyright ? 2014. Published by Elsevier Ltd.
KEYWORDS:
DNA vaccine, H7N9, Hemagglutinin (HA)
PMID:
24631084
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/24631084